Device Trial Radar · NCT06428955
Evaluation of a Monofocal Intraocular Lens
Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Jun 6, 2024
Primary completion
Feb 26, 2026
Study completion Feb 26, 2026
Sponsor
- Lead sponsor
- Carl Zeiss Meditec AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the 3-month visual performance of the CT LUCIA 621P IOL, a hydrophobic aspheric monofocal IOL with a non-constant aspheric optic profile in adult patients 50 years of age or older who are undergoing cataract surgery.
Conditions
- Cataract
Interventions
CT LUCIA 621PDevice
The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens. It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin. The modified C-loop haptic is step-vaulted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monocular best corrected distance visual acuity (CDVA)Time frame: Three (3) Months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Price Vision Group
Indianapolis, Indiana
Huffman & Huffman PSC
Lexington, Kentucky
The Pennsylvania State University and Penn State Health
Hershey, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.